Bli medlem
Bli medlem

Du är här

2014-03-19

Aerocrine: Aerocrine Provides Update on Insurance Coverage of FeNO test in US.

SOLNA, Sweden - 19 March, 2014 - Aerocrine AB (OMX Nordic Exchange:
AERO) announces that Health Care Service Corporation will begin
covering FeNO testing for asthma diagnosis and management effective
April 1, 2014.

Aerocrine has received notification that Health Care Service
Corporation (HCSC) will implement a positive coverage policy for
Fractional exhaled Nitric Oxide (FeNO) testing for the diagnosis and
management of asthma effective April 1, 2014. HCSC, the 5th largest
private payer in the US, provides insurance coverage for 14 million
individuals. HCSC subsidiaries include Blue Cross and Blue Shield
plans of Illinois, Montana, New Mexico, Oklahoma, and Texas.

The new HCSC policy is a positive coverage policy that states FeNO
testing may be considered medically necessary for the diagnosis and
treatment of asthma. This change in policy now allows reimbursement
of claims based on medical necessity. In the last three years,
several of the large Blue Cross and Blue Shield plans have altered
their policies to begin paying for Aerocrine's test. These include:
WellPoint/Anthem Blue Cross Blue Shield, Blue Cross Blue Shield of
Florida, Horizon Blue Cross and Blue Shield, Blue Cross and Blue
Shield of Minnesota and Premera Blue Cross Blue Shield. Aerocrine's
test is now reimbursed by the three largest Blue Cross and Blue
Shield companies in the United States, plans that account for over 40
million covered lives. In all, 64% of US insured lives now have
access to Aerocrine's test nationwide.

HCSC, spent many months reviewing the latest information available and
thoroughly challenged the clinical utility and outcomes information.
This is a very positive change that we hope will encourage other
payers to review their FeNO coverage policies and provide coverage,"
said Scott Myers, CEO, Aerocrine AB "We believe this change at HCSC
will demonstrate to physicians that insurers support FeNO testing to
improve clinical decision making, patient and health economic
outcomes for asthma management."

Insurance companies typically review their medical policies on an
annual basis or whenever substantially new clinical information
becomes available. Currently, seven of the US's top 12 insurers
provide coverage and reimbursement for this test. During the first
quarter; CIGNA and Highmark, the fourth and eighth largest insurers
respectively have maintained a non-coverage policy.

FeNO testing is a two minute, objective, point-of-care breath test
that can be used to identify patients with allergic airway
inflammation. Airway inflammation is widely recognized as the
underlying cause of asthma. Using routine FeNO testing to guide
therapy, particularly inhaled corticosteroid therapy, for asthma
patients has been shown to reduce asthma exacerbations up to 50
percent.

"FeNO is an important addition to the management of many patients with
asthma. It allows the presence of steroid responsive airway
inflammation to be identified. FeNO testing helps clinicians
prescribe the optimal medications and doses for their asthma patients
which can improve patient outcomes," said Dr. Neal Jain, MD, FAAAAI,
FAAP.

Aerocrine's NIOX MINO® is the only FeNO device that is cleared by the
FDA and commercially available in the United States. NIOX MINO is a
simple device that delivers a numerical FeNO score during routine
patient visit.

Asthma is one of this world's most common and costly diseases,
affecting 8-10% of the population and costing more than $50B annually
in the US alone. The disease has no cure and proper diagnosis and
management of the disease are important to obtaining optimal control
of a patient's asthma.

For more information regarding the change in the HCSC policy see the
following link:

http://medicalpolicy.hcsc.net/medicalpolicy/home?corpEntCd=IL1&cat=PENDI...

(Click on Pending Policies to the Left)

For more information, contact:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +46 768 788
379, +970 368 0336

Ken Marshall, Chief Marketing Officer and President Aerocrine, Inc. +919 280 9687

Dr. Kathy Rickard, Chief Medical Officer, Aerocrine AB +919 749 6708

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved
management and care of patients with inflammatory airway diseases. As
the pioneer and leader in technology to monitor and manage airway
inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU) Both
products enable fast and reliable management of airway inflammation
and may therefore play a critical role in more effective diagnosis,
treatment and follow-up of patients with inflammatory airway diseases
such as asthma. Aerocrine is based in Sweden with subsidiaries in the
U.S., Germany and the U.K. Aerocrine shares were listed on the
Stockholm Stock Exchange in 2007.

Aerocrine may be required to disclose the information provided herein
pursuant to the Securities Markets Act and/or the Financial
Instruments Trading Act. The information was submitted for
publication on 03/19/2014 at 4.45 p.m.

-----------------------------------------------------------
http://news.cision.com/aerocrine/r/aerocrine-provides-update-on-insuranc...
http://mb.cision.com/Main/49/9554477/222504.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.